2007 Winter Meeting - London - The Pathological Society of Great ...

P81UNUSUAL SITES TO GO FOR A LEIOMYOSARCOMA{P} A Naveed, B Benatar, N ShaathTameside General Hospital, Ashton, Manchester, United KingdomLeiomyosarcoma is a malignant neoplasm of smooth muscle. It accounts for 10to 20% of the soft tissue sarcoma. It occurs in adults in fifth to seventh decadesaffecting women more than men. Most common sites are extremities.Metastases are usually to lung, liver, brain, and bone. Fifty percent of the caseseventually metastasise and the 5 year survival rate is 60-50%We present an interesting case of a 65 years old lady who was diagnosed withleiomyosarcoma of femur and was treated with surgery and chemotherapy. Sheremained disease free for several years when she developed metastatic diseasein vertebrae and iliac crest. She latter on developed anaemia and was found tohave nodules in stomach and the duodenum. These nodules on biopsy proved tobe metastases from the primary leiomyosarcoma. She then developed changesin her voice and a solitary nodule in her thyroid, which again was the metastaticsarcoma on cytological examination.We will present case history and literature review of this unusual case.P82EMP3 over-expression is associated with oligodendroglialtumours retaining chromosome arms 1; and 19q{P} HK Ng, K Li, JCS PangThe Chinese University of Hong Kong, Hong Kong, ChinaThe epithelial membrane protein 3 (EMP3) gene, located on chromosome19q13, has been implicated as a candidate tumor suppressor gene (TSG) inneuroblastomas and gliomas. The aim of this study was to investigate whetherEMP3 is involved in oligodendroglial tumors (OTs), which frequently carrycombined chromosomes 1p and 19q deletion. We first investigated thetranscript level of EMP3 in a cohort of 57 OTs by quantitative real-time RT-PCR. Our results showed that 10 (18%) tumors had reduced EMP3 expressionlevel compared to normal brains. Six of these tumors carried chromosome19q13 deletion, but no statistical correlation was found between the twoparameters. Intriguingly, a similar proportion (11 of 57, 19%) of tumorsdisplayed EMP3 overexpression, with 8 of them having transcript level >10-fold higher than normal brain. All 11 OTs retained chromosomes 1p36 and19q13 and a significant association was found between EMP3 overexpressionand balanced chromosomes 1p36 and 19q13 (p=0.004). The methylation statusof EMP3 was evaluated by bisulfite sequencing in 29 OTs with diverseexpression levels. All tumors except 3 showed aberrant methylation of EMP3and no correlation was observed between transcript level and methylationstatus, suggesting that methylation alone does not mediate transcriptional downregulationof EMP3 in OTs. In conclusion, our study demonstrates that EMP3overexpression is involved in OTs retaining chromosomes 1p and 19q and doesnot support EMP3 as the target TSG on chromosome 19q13 in OTs.48 Winter Meeting (191 st ) 3–5 January 2007 Scientific Programme